Amboplus SRL
Amboplus reported total assets of 212,418 € at the end of the 2025 financial year (annual accounts filed with the NBB on 18 Jun 2026).
The score of Amboplus shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +18 % Total assets +22 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Amboplus's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 22,092 € | ||||
| Equity | 203,446 € | ||||
| Cash | 12,747 € | ||||
| EBITDA | 43,437 € | ||||
| Total assets | 212,418 € |
Filed annual accounts
- Year ended 30 Nov 2025filed on 18 Jun 2026
- Year ended 30 Nov 2024filed on 11 Jun 2025
- Year ended 30 Nov 2023filed on 17 Jun 2024
- Year ended 30 Nov 2022filed on 06 Jun 2023
- Year ended 30 Nov 2021filed on 08 Jun 2022
Amboplus's financial analysis
- Solvency95.8%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Amboplus
Amboplus's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0886.440.339
- VAT number
- BE0886440339
- Peppol
- Registered · 0208:0886440339 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 Jan 2007
- Registered office
- 8300 Knokke-Heist
- Latest accounts
- 2025 · filed on 18 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Amboplus (SRL) has been based in Knokke-Heist since 2007, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 22,092 € and equity of 203,446 €; its revenue is not published. Its solvency stands at 95.8%, above the median of its sector (44.2%).
Companies similar to Amboplus
Companies in the same business, of comparable size and area, outside its group.
- Castoro Retail sale of pharmaceutical products Pajottegem · balance sheet 213,183 €
- LE Lumeçon Retail sale of pharmaceutical products Brussels · balance sheet 213,394 €
- Pharmacie LERICHE Retail sale of pharmaceutical products Florennes · balance sheet 213,898 €
- Apopark Retail sale of pharmaceutical products Leuven · balance sheet 210,821 €
- Apotheek Sophie Vandewynckele Retail sale of pharmaceutical products Eeklo · balance sheet 214,484 €
- MDB Pharma Retail sale of pharmaceutical products Ghent · balance sheet 214,811 €
- Pharmasolutions Retail sale of pharmaceutical products Linkebeek · balance sheet 215,436 €
- Phidelta Pharma Retail sale of pharmaceutical products Liège · balance sheet 216,336 €
Frequently asked questions about Amboplus
What is the revenue of Amboplus?
Amboplus files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Amboplus?
In Belgium, the VAT number is the company number prefixed with BE: BE0886440339 for Amboplus, if the company is VAT-registered. Its company number (CBE) is 0886.440.339.
Where is the registered office of Amboplus?
According to the CBE register, the registered office of Amboplus is in 8300 Knokke-Heist.
What is the equity of Amboplus?
At the close of the 2025 financial year, the equity of Amboplus amounts to 203,446 €, a solvency of 95.8% of total assets.
Who manages Amboplus?
The register lists 2 active mandates at Amboplus. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Amboplus
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →